Kigtropin to marka syntetycznego człowieka,Kigtropin to najlepsza somatropina HGH na rynku, najskuteczniejsza i najskuteczniejsza osoba, jaką można uzyskać, Kigtropin jest zaprojektowany. Wysyłamy zamówienie z USA, czyna, i UE. Jesteśmy dystrybutorem?kigtropin HGH hurtownia? kigtropina HGH, Proszę uzyskać więcej kigtropin HGH Chiny (Kontynent) producenci, eksporterzy, dostawców, fabryki, Firmy z Chin .
Kigtropin jest ludzkim hormonem wzrostu (hGH) Somatropina wytwarzana przy użyciu technologii rekombinacji DNA identycznej z naturalnie wytwarzanym przez organizm HGH.
Zaburzenia wzrostu u dzieci z powodu endogennego niedoboru hormonu wzrostu (GHD).
U dorosłych z niedoborem hormonu wzrostu,KIGTROPIN redukuje masę tłuszczu,zwiększa masę mięśniową i poprawia energię,witalność i subiektywne samopoczucie. U pacjentów z ciężkimi oparzeniami,Zanik mięśni związany z AIDS,lub w trakcie poważnych operacji,KIGTROPIN wspomaga gojenie się ran,osłabia odpowiedź białkowo-kataboliczną i poprawia stan azotowy całego organizmu po operacji.
Kigtropin comes as a freeze dried white powder – 10 x 10 IU (3.3 mg) fiolek w pudełku. Like several others it started as a made up brand name which became popular due to good reviews in the bodybuilding community. It is manufactured by an unknown Chinese lab – which seems to be a common practice some Chinese companies use to avoid the HGH legality issues
In patients who continue growth hormone therapy after childhood GHD, the recommended dose to restart is 0.2 - 0.5 mg per day. The dose should be gradually increased or decreased according to individual patient requirements as determined by the IGF-I concentration.
In adults with adult-onset GHD, therapy should start with a low dose, 0.15 - 0.3 mg per day. The dose should be gradually increased according to individual patient requirements as determined by the IGF-I concentration.
In both cases treatment goal should be insulin-like growth factor (IGF-I) concentrations within 2 SDS from the age corrected mean. Patients with normal IGF-I concentrations at the start of the treatment should be administered growth hormone up to an IGF-I level into the upper range of normal, not exceeding the 2 SDS. Clinical response and side effects may also be used as guidance for dose titration. It is recognized that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation. The maintenance dose rarely exceeds 1.0 mg per day. Women may require higher doses than men, with men showing an increasing IGF-I sensitivity over time. This means that there is a risk that women, especially those on oral oestrogen replacement are under-treated while men are over-treated. The accuracy of the growth hormone dose should therefore be controlled every 6 miesiące. As normal physiological growth hormone production decreases with age, dose requirements may be reduced.
Kigtropin for Elderly:
In patients above 60 lata, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements. The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day.
How to Inject:
The subcutaneous administration of growth hormone may lead to loss or increase of adipose tissue at the injection site. W związku z tym, injection sites should be alternated.
The injection should be given subcutaneously and the site varied to prevent lipoatrophy.
